Merck Stock Ran On A Checklist Published In Advance

The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.

Merck (MRK) stock is up 86.8% over the past year, against 20.6% for the S&P 500. A move that size usually looks like new information arriving. The case behind this one was largely on the public record before the run began: the products meant to offset the KEYTRUDA patent expiry had been named, and two of them were already booking rising revenue.

The Quarter’s Falling Top Line Had One Address

The weakness the market was looking at had a date on it. Merck paused GARDASIL shipments to China in February 2025 to work down channel inventory that had built up above normal levels. By fiscal Q2 2025 reported revenue was down 2%, and the company’s own breakdown pinned that on a roughly $1.3 billion decline in GARDASIL sales in China, worth 9 percentage points of growth; excluding those sales, the rest of the business grew 7%. Trailing-twelve-month revenue growth as of fiscal Q2 2025 was still positive at 1.8%, but decelerating, so a screener showed a drugmaker going sideways when the shortfall sat in one vaccine in one country.

WINREVAIR And CAPVAXIVE Were Already In The Numbers

WINREVAIR, for pulmonary arterial hypertension, had passed $1 billion of cumulative sales within 15 months of launch and booked $336 million in fiscal Q2 2025. CAPVAXIVE, the adult pneumococcal conjugate vaccine, went from $50 million in fiscal Q4 2024 to $129 million in fiscal Q2 2025. Three weeks before the run began, management named the offsets to the KEYTRUDA patent expiry outright: WINREVAIR first, then CAPVAXIVE, then clesrovimab, with enlicitide and sac-TMT behind them, adding that the Street was under-appreciating that pipeline.

Through the surge year the two selling products kept climbing: WINREVAIR reached $588 million in fiscal Q2 2026, up 75% ex-currency, and CAPVAXIVE $184 million, up 40% on the same basis. Against total revenue of $16.6 billion in that quarter, these are still small lines, and that is the point: what a reader could check a year early was not their size but their slope. Growth that comes out of products already approved and already selling is the kind of quality the Trefis High Quality Portfolio looks for in its holdings.

The Sales Lines Were Legible, The Start Date Was Not

The signs were real, dated and specific. What they were not is a timing signal. In the weeks before the run, options pricing gave no hint: implied volatility eased from the 73rd percentile of its trailing one-year range in early July 2025 to the 63rd by August 8, 2025, which points to a smaller expected move, and says nothing at all about direction. Large-cap pharma broadly outran the wider market, though individual outcomes diverged significantly: Pfizer (PFE) returned 20.5% over the same window, while Johnson & Johnson (JNJ) gained 59.0% and Eli Lilly (LLY) surged 84.6%. The reward went to picking within the sector, not to owning it. Merck has since raised and narrowed its full-year 2026 revenue guidance, which is the shape worth hunting elsewhere: an outlook that keeps moving up is what the Guidance Momentum screen is built to surface.

One Good Read Does Not Repeat On Schedule

Reading Merck correctly a year early paid heavily, and it is still one good call rather than a method. Compounding comes from a process applied across many names, which is what a rules-based basket such as the Trefis High Quality Portfolio is for. That portfolio has a track record of outpacing the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.